Maureen Cox, PhD, and Jumana Abbadi, MD, explain how macrophage-derived BDNF drives sensory nerve growth into triple-negative ...

The FDA granted accelerated approval to RP1 (vusolimogene oderparepvec; Tudriqev), an oncolytic virus therapy, in combination ...

Dr. Monty Pal concludes his discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by summarizing how he ...

Mark Agulnik, MD, discusses the trend away from surgery and toward targeted treatment of progressive desmoid tumors, and how ...

The FDA has cleared an investigational new drug (IND) application for Bria-PROS+, a personalized, off-the-shelf, whole-cell ...

Phase 3 SENOMAC randomized 2766 patients across five countries to completion ALND vs omission after up to two sentinel-node ...

Dr. Monty Pal concludes the program by discussing how the treatment landscape for advanced renal cell carcinoma (RCC) may evolve as new clinical evidence emerges.

HR-positive disease accounts for approximately 70% to 80% of breast cancer diagnoses and carries a risk of recurrence that ...

Sagar Lonial, MD, discusses why to take an individualized approach despite the trial's findings supporting discontinuation of lenalidomide at 2 years. Sagar Lonial, MD, of the Winship Cancer Institute ...

FDA tentatively OKs cabozantinib capsules for RCC, HCC and epNET, with dose-conversion guidance, error warning and improved ...

City of Hope's Dr Ravi Salgia explains a new national trial using biomarkers to predict immunotherapy success in advanced non ...

Patrick Borgen, MD, built Brooklyn's breast cancer program from 47 patients to 8,000. Now he and Joshua Feinberg, MD discuss ...